HIV-1 subtypes and drug resistance profiles in a cohort of heterosexual patients in Istanbul, Turkey (Q41009267)

25 September 2017

title

HIV-1 subtypes and drug resistance profiles in a cohort of heterosexual patients in Istanbul, Turkey (English)

1 reference

25 September 2017

1 reference

Nadine Lübke

0 references

Rolf Kaiser

object named as

Rolf Kaiser

1 reference

25 September 2017

Muammer Osman Köksal

1 reference

25 September 2017

Hayati Beka

1 reference

25 September 2017

Nadine Lübke

1 reference

25 September 2017

Jens Verheyen

1 reference

25 September 2017

Haluk Eraksoy

1 reference

25 September 2017

Atahan Cagatay

1 reference

25 September 2017

Baki Akgül

1 reference

25 September 2017

Ali Agacfidan

1 reference

25 September 2017

language of work or name

1 reference

28 April 2015

1 reference

Medical Microbiology and Immunology

25 September 2017

published in

1 reference

25 September 2017

volume

204

1 reference

25 September 2017

1 reference

25 September 2017

page(s)

551-555

1 reference

HIV in Turkey, a country bridging the Islamic world and Europe.

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

Molecular epidemiology of HIV in a cohort of men having sex with men from Istanbul.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

Accessory mutations maintain stability in drug-resistant HIV-1 protease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

Drug resistance in HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

Prevalence of the mutational pattern E44D/A and/or V118I in the reverse transcriptase (RT) gene of HIV-1 in relation to treatment with nucleoside analogue RT inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

HIV cure research: advances and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

Human immunodeficiency virus reverse transcriptase and protease sequence database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

Molecular Epidemiological Analysis of HIV-1 pol Gene Sequences Isolated in Istanbul, Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

Characterization of Genotypic and Phenotypic Changes in HIV-1-Infected Patients with Virologic Failure on an Etravirine-Containing Regimen in the DUET-1 and DUET-2 Clinical Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

Prevalence of C-terminal gag cleavage site mutations in HIV from therapy-naïve patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

Negative effect of the M184V mutation in HIV-1 reverse transcriptase on initiation of viral DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nuleoside analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

Improved virological and immunological efficacy of resistance-guided switch in antiretroviral therapy: a Frankfurt HIV cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

Determination of drug resistance and virus typology in HIV-1-positive pediatric patients in Istanbul, Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-015-0419-9

Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling

21 January 2018

1 reference

12 December 2020

HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes

1 reference

12 December 2020

Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors

1 reference

12 December 2020

Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.

1 reference

12 December 2020

HIV prevalence and route of transmission in Turkish immigrants living in North-Rhine Westphalia, Germany

1 reference

12 December 2020

HIV-1 subtypes and primary antiretroviral resistance mutations in antiretroviral therapy naive HIV-1 infected individuals in Turkey.

1 reference

12 December 2020

Prediction of HIV-1 coreceptor usage (tropism) by sequence analysis using a genotypic approach

1 reference

12 December 2020

The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness

1 reference

12 December 2020

European recommendations for the clinical use of HIV drug resistance testing: 2011 update.

1 reference

12 December 2020

10.1007/S00430-015-0419-9

Identifiers

DOI

1 reference

25 September 2017

1 reference